R&D Innovative direct delivery strategies to unlock oligonucleot... Oligo therapies are emerging as promising therapeutics with the potential to address previously untreatable conditions.
R&D DiaMedica’s novel biologic basal dilator: Bringing hope to p... pharmaphorum spoke with DiaMedica’s CEO, Rick Pauls, about the company's efforts in preeclampsia, early-onset preeclampsia, and ischaemic stroke.
R&D Sponsored 12 Questions with Faruk Uzman Find out more about Faruk Uzman, VP EMEA at Boston Scientific, in a new 12 Questions With.
R&D The conflict in the Middle East is exposing dangerous prepar... If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.
R&D LSX2026: Endogenous tissue restoration in vascular disease –... Paulo Neves, CMO of Xeltis, discusses transformative implants that enable the natural creation of living and long-lasting vessels.
R&D Neuroplasticity modulators as innovative potential disease-m... In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by licensing a drug for the rare genetic disorder Fragile X syndrome
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
